Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars

Set Alert for Biosimilars

Awards Offers Two Weeks Of Online Networking

From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.

Generic Drugs Biosimilars

Podcast: The UK's New Biosimilars Licensing Pathway

In this podcast discussion, Generics Bulletin editor David Wallace talks to Duncan Emerton, director of Custom Intelligence and Analytics for Informa Pharma Intelligence, about the UK's new licensing procedure for biosimilars.

Biosimilars Regulation

Roche’s Biosimilar Losses Could Be Closer To CHF5bn

Roche entered the year with a projected hit to revenues from multi-source biosimilar competition to its three leading biologics. However, the number was increased at the half-year mark and could be set to ratchet up further, according to management.

Biosimilars Sales & Earnings

Australia Changes Patent Notification Requirements

Australia’s Therapeutic Goods Administration has set out proposals for a change to early-notification requirements for generic and biosimilar sponsors.

Regulation Intellectual Property

Ultomiris FDA Approval Gives Soliris Biosimilars Bigger Hurdle

Alexion Pharmaceuticals’ Soliris (eculizumab) blockbuster represents a significant opportunity for biosimilar sponsors around the globe. Ahead of anticipated US competition in 2025, the originator has added a new formulation for next-generation product Ultomiris (ravulizumab-cwvz).

Biosimilars FDA

Formycon Raises Fresh Capital To Drive Biosimilar Development

German biosimilars firm Formycon has raised tens of millions of euros through an issue of new shares, with the cash earmarked for its burgeoning pipeline of wholly-owned biosimilars, including a Lucentis (ranibizumab) candidate being developed with Coherus.

Biosimilars Financing
See All
UsernamePublicRestriction

Register